Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1667
Title: Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation
Authors: Forsyth, Cecily J ;Joshi, M.;Taper, J.;Rowlings, P.;Campbell, P.;Crispin, P.;Harvey, M.;Underhill, C.;Bayley, A.;Byth, K.;Huang, G.;Hertzberg, M.
Affliation: Central Coast Local Health District
Gosford Hospital
Issue Date: Sep-2019
Source: 61(1):91-97
Journal title: Leukemia & lymphoma
Department: Haematology
Abstract: Patients with relapsed-refractory diffuse large B-cell lymphoma (RR-DLBCL) ineligible for autologous stem cell transplantation (autoSCT) have poor survival. Thirty transplant-ineligible patients older than 60 years were administered rituximab 375 mg/m2 day 1, ifosfamide 1333 mg/m(2) days 1 to 3, and etoposide 80 mg/m(2) days 1 to 3 (R-IE) every 21 days for 6 cycles plus 2 doses of rituximab. Revised international prognostic index 3-4 was seen in 53% and prior rituximab exposure in 60%. The complete and overall response rates were 55% and 76%, respectively. Median progression free survival (PFS) and overall survival were 23 and 24 months, respectively. Patients relapsing within 12 months of prior treatment had a median PFS of 2.5 months compared to 23 months for those relapsing beyond 12 months. Grade 3-4 thrombocytopenia and neutropenia occurred in one and eight patients, respectively. R-IE is an effective, well tolerated regimen in RR-DLBCL patients not fit for autoSCT.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1667
DOI: 10.1080/10428194.2019.1660968
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/31512531
ISSN: 1026-8022
Publicaton type: Journal Article
Keywords: Haematology
Hematology
Cancer
Appears in Collections:Haematology

Show full item record

Page view(s)

16
checked on Jan 27, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.